Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS).

Chiari R, Ricciuti B, Landi L, Morelli AM, Delmonte A, Spitaleri G, Cortinovis DL, Lamberti G, Facchinetti F, Pilotto S, Verusio C, Chella A, Bonanno L, Galetta D, Cappuzzo F.

Clin Lung Cancer. 2019 Jun 18. pii: S1525-7304(19)30154-8. doi: 10.1016/j.cllc.2019.06.012. [Epub ahead of print]

PMID:
31607443
2.

Crizotinib in MET deregulated or ROS1 rearranged pretreated non-small-cell lung cancer (METROS): a phase II, prospective, multicentre, two-arms trial.

Landi L, Chiari R, Tiseo M, D'Incà F, Dazzi C, Chella A, Delmonte A, Bonanno L, Giannarelli D, Cortinovis DL, De Marinis F, Borra G, Morabito A, Gridelli C, Galetta D, Barbieri F, Grossi F, Capelletto E, Minuti G, Mazzoni F, Verusio C, Bria E, Alì G, Bruno R, Proietti A, Fontanini G, Crinò L, Cappuzzo F.

Clin Cancer Res. 2019 Aug 15. pii: clincanres.0994.2019. doi: 10.1158/1078-0432.CCR-19-0994. [Epub ahead of print]

PMID:
31416808
3.

Peritoneal carcinomatosis in non-small-cell lung cancer: retrospective multicentric analysis and literature review.

Abbate MI, Cortinovis DL, Tiseo M, Vavalà T, Cerea G, Toschi L, Canova S, Colonese F, Bidoli P.

Future Oncol. 2019 Mar;15(9):989-994. doi: 10.2217/fon-2018-0469. Epub 2019 Jan 25. Review.

PMID:
30681378
4.

Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients' selection.

Banna GL, Passiglia F, Colonese F, Canova S, Menis J, Addeo A, Russo A, Cortinovis DL.

Crit Rev Oncol Hematol. 2018 Sep;129:27-39. doi: 10.1016/j.critrevonc.2018.06.016. Epub 2018 Jun 23. Review.

PMID:
30097235
5.

Blood cell count indexes as predictors of outcomes in advanced non-small-cell lung cancer patients treated with Nivolumab.

Putzu C, Cortinovis DL, Colonese F, Canova S, Carru C, Zinellu A, Paliogiannis P.

Cancer Immunol Immunother. 2018 Sep;67(9):1349-1353. doi: 10.1007/s00262-018-2182-4. Epub 2018 Jun 9.

PMID:
29947960
6.

Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer.

Fehrenbacher L, von Pawel J, Park K, Rittmeyer A, Gandara DR, Ponce Aix S, Han JY, Gadgeel SM, Hida T, Cortinovis DL, Cobo M, Kowalski DM, De Marinis F, Gandhi M, Danner B, Matheny C, Kowanetz M, He P, Felizzi F, Patel H, Sandler A, Ballinger M, Barlesi F.

J Thorac Oncol. 2018 Aug;13(8):1156-1170. doi: 10.1016/j.jtho.2018.04.039. Epub 2018 May 17. Erratum in: J Thorac Oncol. 2018 Nov;13(11):1800.

7.

[Metastatic lung adenocarcinoma. Nivolumab as second line treatment: between unresolved issues and promising future. A case report.]

Cortinovis DL.

Recenti Prog Med. 2018 Mar;109(3):197e-201e. doi: 10.1701/2876.29005. Italian.

PMID:
29565054
8.

Chemotherapy-induced nausea and vomiting (CINV) in patients with advanced lung cancer during the first-line treatment: assessment by physicians, nurses, and patients from an Italian multicenter survey.

Carnio S, Galetta D, Scotti V, Cortinovis DL, Antonuzzo A, Pisconti S, Rossi A, Martelli O, Cecere FL, Lunghi A, Del Conte A, Montagna ES, Topulli J, Pelizzoni D, Rapetti SG, Gianetta M, Pacchiana MV, Pegoraro V, Cataldo N, Bria E, Novello S.

Support Care Cancer. 2018 Jun;26(6):1841-1849. doi: 10.1007/s00520-017-4004-1. Epub 2017 Dec 21.

PMID:
29270827
9.

How to describe univariate data.

Canova S, Cortinovis DL, Ambrogi F.

J Thorac Dis. 2017 Jun;9(6):1741-1743. doi: 10.21037/jtd.2017.05.80.

10.

Focus on Nivolumab in NSCLC.

Cortinovis DL, Canova S, Abbate M, Colonese F, Bidoli P.

Front Med (Lausanne). 2016 Dec 13;3:67. doi: 10.3389/fmed.2016.00067. eCollection 2016. Review.

11.

Gemcitabine-induced thrombocytosis as a potential predictive factor in non-small cell lung cancer: analysis of 318 patients.

Canova S, Cicchiello F, Agustoni F, Bianchini G, Abbate MI, Bidoli P, Cortinovis DL.

Tumori. 2017 Mar 24;103(2):143-147. doi: 10.5301/tj.5000584. Epub 2016 Nov 28.

PMID:
28009425
12.

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, De Marinis F, Turna H, Lee JS, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara DR; OAK Study Group.

Lancet. 2017 Jan 21;389(10066):255-265. doi: 10.1016/S0140-6736(16)32517-X. Epub 2016 Dec 13. Erratum in: Lancet. 2017 Apr 8;389(10077):e5.

PMID:
27979383
13.

What are the options for non-small-cell lung cancer patients post second-line therapy?

Cortinovis DL, Canova S, Bidoli P.

Future Oncol. 2015;11(17):2379-82. doi: 10.2217/FON.15.159. Epub 2015 Aug 13. Review. No abstract available.

PMID:
26270000
14.

Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer.

Bidoli P, Cortinovis DL, Colombo I, Crippa A, Cicchiello F, Villa F, Cazzaniga ME, Altomare G.

J Thorac Oncol. 2010 Oct;5(10):1662-3. doi: 10.1097/JTO.0b013e3181ec1729.

15.

FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer.

Cortinovis DL, Andriani F, Livio A, Fabbri A, Perrone F, Marcomini B, Pilotti S, Mariani L, Bidoli P, Bajetta E, Roz L, Sozzi G.

Curr Cancer Drug Targets. 2008 Aug;8(5):342-8.

PMID:
18690840

Supplemental Content

Loading ...
Support Center